-
-
-
-
-
-
-
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
-
-
-
-
-
-
-
Takeda (TAK) Announces FDA Grants Priority Review of Maribavir for Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatme
-
-
-
-
-
72,087 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

